Palvella Therapeutics reports preliminary Dec 31, 2025 cash of $55.9M

PALVELLA THERAPEUTICS, INC.

Preliminary unaudited cash, cash equivalents and marketable securities as of Dec 31, 2025: $55.9 million.
Amount subject to change upon completion of financial close procedures; not audited by Ernst & Young.
No other financial results provided; full year 2025 results pending.

item 2.02

PALVELLA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-019143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.